nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—SLC22A2—Vinblastine—head and neck cancer	0.0723	0.153	CbGbCtD
Imatinib—ABCG2—Fluorouracil—head and neck cancer	0.0576	0.122	CbGbCtD
Imatinib—CYP2D6—Hydroxyurea—head and neck cancer	0.0512	0.108	CbGbCtD
Imatinib—ABCG2—Docetaxel—head and neck cancer	0.044	0.0929	CbGbCtD
Imatinib—ALB—Fluorouracil—head and neck cancer	0.0397	0.0838	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0325	0.0686	CbGbCtD
Imatinib—CYP3A7—Docetaxel—head and neck cancer	0.0325	0.0686	CbGbCtD
Imatinib—CYP3A5—Docetaxel—head and neck cancer	0.0244	0.0515	CbGbCtD
Imatinib—CYP1A2—Fluorouracil—head and neck cancer	0.0237	0.0502	CbGbCtD
Imatinib—CYP2C9—Fluorouracil—head and neck cancer	0.0214	0.0452	CbGbCtD
Imatinib—ABCB1—Vinblastine—head and neck cancer	0.0192	0.0406	CbGbCtD
Imatinib—CYP2D6—Vinblastine—head and neck cancer	0.0181	0.0383	CbGbCtD
Imatinib—ABCB1—Docetaxel—head and neck cancer	0.0159	0.0335	CbGbCtD
Imatinib—CA6—submandibular gland—head and neck cancer	0.0152	0.117	CbGeAlD
Imatinib—CYP3A4—Vinblastine—head and neck cancer	0.0115	0.0243	CbGbCtD
Imatinib—CYP3A4—Docetaxel—head and neck cancer	0.0095	0.0201	CbGbCtD
Imatinib—CA6—saliva—head and neck cancer	0.00549	0.0421	CbGeAlD
Imatinib—CA6—ear—head and neck cancer	0.00502	0.0385	CbGeAlD
Imatinib—CA3—ear—head and neck cancer	0.00475	0.0364	CbGeAlD
Imatinib—DDR1—hair follicle—head and neck cancer	0.00425	0.0326	CbGeAlD
Imatinib—ORM1—saliva—head and neck cancer	0.00292	0.0224	CbGeAlD
Imatinib—CA6—exocrine gland—head and neck cancer	0.00278	0.0213	CbGeAlD
Imatinib—CA6—hair follicle—head and neck cancer	0.00264	0.0203	CbGeAlD
Imatinib—ABCA3—parotid gland—head and neck cancer	0.00252	0.0193	CbGeAlD
Imatinib—ABCA3—saliva-secreting gland—head and neck cancer	0.00241	0.0185	CbGeAlD
Imatinib—DDR1—parotid gland—head and neck cancer	0.00232	0.0178	CbGeAlD
Imatinib—DDR1—saliva-secreting gland—head and neck cancer	0.00222	0.017	CbGeAlD
Imatinib—CA6—mouth—head and neck cancer	0.00208	0.0159	CbGeAlD
Imatinib—CA3—mouth—head and neck cancer	0.00197	0.0151	CbGeAlD
Imatinib—DDR1—trachea—head and neck cancer	0.00172	0.0131	CbGeAlD
Imatinib—KIT—exocrine gland—head and neck cancer	0.00161	0.0124	CbGeAlD
Imatinib—ABCA3—thyroid gland—head and neck cancer	0.00147	0.0113	CbGeAlD
Imatinib—CA6—parotid gland—head and neck cancer	0.00145	0.0111	CbGeAlD
Imatinib—PIP4K2C—parotid gland—head and neck cancer	0.00143	0.011	CbGeAlD
Imatinib—CA6—saliva-secreting gland—head and neck cancer	0.00138	0.0106	CbGeAlD
Imatinib—PIP4K2C—saliva-secreting gland—head and neck cancer	0.00137	0.0105	CbGeAlD
Imatinib—CA3—parotid gland—head and neck cancer	0.00137	0.0105	CbGeAlD
Imatinib—DDR1—thyroid gland—head and neck cancer	0.00136	0.0104	CbGeAlD
Imatinib—ABCA3—head—head and neck cancer	0.0013	0.01	CbGeAlD
Imatinib—KIT—mouth—head and neck cancer	0.00121	0.00924	CbGeAlD
Imatinib—CA3—connective tissue—head and neck cancer	0.0012	0.00923	CbGeAlD
Imatinib—CA7—trachea—head and neck cancer	0.0011	0.00845	CbGeAlD
Imatinib—PIP4K2C—trachea—head and neck cancer	0.00106	0.00811	CbGeAlD
Imatinib—NQO2—parotid gland—head and neck cancer	0.00105	0.00807	CbGeAlD
Imatinib—KIT—neck—head and neck cancer	0.00103	0.0079	CbGeAlD
Imatinib—NQO2—saliva-secreting gland—head and neck cancer	0.00101	0.00773	CbGeAlD
Imatinib—PDGFRB—neck—head and neck cancer	0.00101	0.00771	CbGeAlD
Imatinib—CA2—exocrine gland—head and neck cancer	0.000956	0.00732	CbGeAlD
Imatinib—LCK—trachea—head and neck cancer	0.00094	0.0072	CbGeAlD
Imatinib—PDGFRA—connective tissue—head and neck cancer	0.000924	0.00708	CbGeAlD
Imatinib—ABCA3—lymph node—head and neck cancer	0.000914	0.007	CbGeAlD
Imatinib—CA2—hair follicle—head and neck cancer	0.000911	0.00698	CbGeAlD
Imatinib—ABL2—thyroid gland—head and neck cancer	0.000885	0.00678	CbGeAlD
Imatinib—CA12—connective tissue—head and neck cancer	0.000853	0.00654	CbGeAlD
Imatinib—DDR1—lymph node—head and neck cancer	0.000843	0.00646	CbGeAlD
Imatinib—KIT—parotid gland—head and neck cancer	0.000839	0.00643	CbGeAlD
Imatinib—PIP4K2C—thyroid gland—head and neck cancer	0.000838	0.00642	CbGeAlD
Imatinib—PDGFRB—parotid gland—head and neck cancer	0.00082	0.00628	CbGeAlD
Imatinib—CSF1R—connective tissue—head and neck cancer	0.000814	0.00623	CbGeAlD
Imatinib—KIT—saliva-secreting gland—head and neck cancer	0.000804	0.00616	CbGeAlD
Imatinib—CA3—thyroid gland—head and neck cancer	0.0008	0.00613	CbGeAlD
Imatinib—PDGFRB—saliva-secreting gland—head and neck cancer	0.000785	0.00602	CbGeAlD
Imatinib—NQO2—trachea—head and neck cancer	0.000778	0.00596	CbGeAlD
Imatinib—PDGFRA—trachea—head and neck cancer	0.000776	0.00594	CbGeAlD
Imatinib—CA6—head—head and neck cancer	0.000749	0.00574	CbGeAlD
Imatinib—LCK—thyroid gland—head and neck cancer	0.000744	0.0057	CbGeAlD
Imatinib—PIP4K2C—head—head and neck cancer	0.000743	0.00569	CbGeAlD
Imatinib—KIT—connective tissue—head and neck cancer	0.000739	0.00566	CbGeAlD
Imatinib—ABL1—parotid gland—head and neck cancer	0.000731	0.0056	CbGeAlD
Imatinib—PDGFRB—connective tissue—head and neck cancer	0.000722	0.00553	CbGeAlD
Imatinib—CA12—trachea—head and neck cancer	0.000716	0.00549	CbGeAlD
Imatinib—CA2—mouth—head and neck cancer	0.000715	0.00548	CbGeAlD
Imatinib—CA3—head—head and neck cancer	0.00071	0.00544	CbGeAlD
Imatinib—KIT—epithelium—head and neck cancer	0.000701	0.00537	CbGeAlD
Imatinib—ABL1—saliva-secreting gland—head and neck cancer	0.0007	0.00536	CbGeAlD
Imatinib—PDGFRB—epithelium—head and neck cancer	0.000685	0.00525	CbGeAlD
Imatinib—CSF1R—trachea—head and neck cancer	0.000683	0.00523	CbGeAlD
Imatinib—PDGFRA—lymphoid tissue—head and neck cancer	0.000676	0.00518	CbGeAlD
Imatinib—ABL1—connective tissue—head and neck cancer	0.000643	0.00493	CbGeAlD
Imatinib—KIT—trachea—head and neck cancer	0.00062	0.00475	CbGeAlD
Imatinib—NQO2—thyroid gland—head and neck cancer	0.000615	0.00471	CbGeAlD
Imatinib—PDGFRA—thyroid gland—head and neck cancer	0.000614	0.0047	CbGeAlD
Imatinib—CA2—neck—head and neck cancer	0.000611	0.00468	CbGeAlD
Imatinib—PDGFRB—trachea—head and neck cancer	0.000606	0.00464	CbGeAlD
Imatinib—CSF1R—lymphoid tissue—head and neck cancer	0.000595	0.00456	CbGeAlD
Imatinib—Skin exfoliation—Docetaxel—head and neck cancer	0.000554	0.00248	CcSEcCtD
Imatinib—Fluid retention—Docetaxel—head and neck cancer	0.000551	0.00247	CcSEcCtD
Imatinib—ABL2—lymph node—head and neck cancer	0.00055	0.00421	CbGeAlD
Imatinib—NQO2—head—head and neck cancer	0.000546	0.00418	CbGeAlD
Imatinib—PDGFRA—head—head and neck cancer	0.000544	0.00417	CbGeAlD
Imatinib—Alopecia—Vinblastine—head and neck cancer	0.000544	0.00243	CcSEcCtD
Imatinib—CSF1R—thyroid gland—head and neck cancer	0.00054	0.00414	CbGeAlD
Imatinib—KIT—lymphoid tissue—head and neck cancer	0.00054	0.00414	CbGeAlD
Imatinib—ABL1—trachea—head and neck cancer	0.00054	0.00414	CbGeAlD
Imatinib—Dry skin—Fluorouracil—head and neck cancer	0.000535	0.0024	CcSEcCtD
Imatinib—Oesophagitis—Docetaxel—head and neck cancer	0.00053	0.00237	CcSEcCtD
Imatinib—PDGFRB—lymphoid tissue—head and neck cancer	0.000528	0.00404	CbGeAlD
Imatinib—Neoplasm—Docetaxel—head and neck cancer	0.000525	0.00235	CcSEcCtD
Imatinib—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000522	0.00234	CcSEcCtD
Imatinib—PIP4K2C—lymph node—head and neck cancer	0.00052	0.00399	CbGeAlD
Imatinib—Lightheadedness—Docetaxel—head and neck cancer	0.000519	0.00232	CcSEcCtD
Imatinib—Pulmonary oedema—Docetaxel—head and neck cancer	0.000517	0.00231	CcSEcCtD
Imatinib—Muscular weakness—Fluorouracil—head and neck cancer	0.000515	0.0023	CcSEcCtD
Imatinib—Angiopathy—Hydroxyurea—head and neck cancer	0.000509	0.00228	CcSEcCtD
Imatinib—Dysphagia—Fluorouracil—head and neck cancer	0.000504	0.00226	CcSEcCtD
Imatinib—Sepsis—Docetaxel—head and neck cancer	0.000504	0.00225	CcSEcCtD
Imatinib—Chills—Hydroxyurea—head and neck cancer	0.000503	0.00225	CcSEcCtD
Imatinib—CA12—head—head and neck cancer	0.000502	0.00385	CbGeAlD
Imatinib—Eosinophilia—Fluorouracil—head and neck cancer	0.000499	0.00224	CcSEcCtD
Imatinib—CA2—parotid gland—head and neck cancer	0.000498	0.00381	CbGeAlD
Imatinib—CA3—lymph node—head and neck cancer	0.000497	0.00381	CbGeAlD
Imatinib—Ill-defined disorder—Vinblastine—head and neck cancer	0.000497	0.00222	CcSEcCtD
Imatinib—Alopecia—Hydroxyurea—head and neck cancer	0.000496	0.00222	CcSEcCtD
Imatinib—Anaemia—Vinblastine—head and neck cancer	0.000495	0.00222	CcSEcCtD
Imatinib—CA1—lymphoid tissue—head and neck cancer	0.000494	0.00379	CbGeAlD
Imatinib—SLC47A1—thyroid gland—head and neck cancer	0.000493	0.00378	CbGeAlD
Imatinib—Angina pectoris—Fluorouracil—head and neck cancer	0.000491	0.0022	CcSEcCtD
Imatinib—KIT—thyroid gland—head and neck cancer	0.000491	0.00376	CbGeAlD
Imatinib—Erythema—Hydroxyurea—head and neck cancer	0.000488	0.00219	CcSEcCtD
Imatinib—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000484	0.00217	CcSEcCtD
Imatinib—Malaise—Vinblastine—head and neck cancer	0.000483	0.00216	CcSEcCtD
Imatinib—Vertigo—Vinblastine—head and neck cancer	0.000481	0.00215	CcSEcCtD
Imatinib—CSF1R—head—head and neck cancer	0.000479	0.00367	CbGeAlD
Imatinib—Leukopenia—Vinblastine—head and neck cancer	0.000479	0.00215	CcSEcCtD
Imatinib—PDGFRB—thyroid gland—head and neck cancer	0.000479	0.00367	CbGeAlD
Imatinib—Pancytopenia—Fluorouracil—head and neck cancer	0.000479	0.00214	CcSEcCtD
Imatinib—CA2—saliva-secreting gland—head and neck cancer	0.000477	0.00365	CbGeAlD
Imatinib—Deafness—Docetaxel—head and neck cancer	0.000471	0.00211	CcSEcCtD
Imatinib—ABL1—lymphoid tissue—head and neck cancer	0.00047	0.0036	CbGeAlD
Imatinib—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000469	0.0021	CcSEcCtD
Imatinib—Hepatic failure—Docetaxel—head and neck cancer	0.000469	0.0021	CcSEcCtD
Imatinib—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000464	0.00208	CcSEcCtD
Imatinib—Convulsion—Vinblastine—head and neck cancer	0.000464	0.00208	CcSEcCtD
Imatinib—Hypertension—Vinblastine—head and neck cancer	0.000462	0.00207	CcSEcCtD
Imatinib—LCK—lymph node—head and neck cancer	0.000462	0.00354	CbGeAlD
Imatinib—ABCG2—parotid gland—head and neck cancer	0.000461	0.00353	CbGeAlD
Imatinib—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00046	0.00206	CcSEcCtD
Imatinib—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000453	0.00203	CcSEcCtD
Imatinib—Pneumonia—Fluorouracil—head and neck cancer	0.000452	0.00203	CcSEcCtD
Imatinib—Anaemia—Hydroxyurea—head and neck cancer	0.000451	0.00202	CcSEcCtD
Imatinib—Discomfort—Vinblastine—head and neck cancer	0.00045	0.00202	CcSEcCtD
Imatinib—Infestation NOS—Fluorouracil—head and neck cancer	0.00045	0.00201	CcSEcCtD
Imatinib—Infestation—Fluorouracil—head and neck cancer	0.00045	0.00201	CcSEcCtD
Imatinib—Atrial fibrillation—Docetaxel—head and neck cancer	0.000445	0.00199	CcSEcCtD
Imatinib—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000443	0.00199	CcSEcCtD
Imatinib—ABCG2—saliva-secreting gland—head and neck cancer	0.000441	0.00338	CbGeAlD
Imatinib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000441	0.00197	CcSEcCtD
Imatinib—Myocardial infarction—Fluorouracil—head and neck cancer	0.000441	0.00197	CcSEcCtD
Imatinib—Dermatitis bullous—Docetaxel—head and neck cancer	0.000441	0.00197	CcSEcCtD
Imatinib—Malaise—Hydroxyurea—head and neck cancer	0.00044	0.00197	CcSEcCtD
Imatinib—Stomatitis—Fluorouracil—head and neck cancer	0.000438	0.00196	CcSEcCtD
Imatinib—CA2—connective tissue—head and neck cancer	0.000438	0.00336	CbGeAlD
Imatinib—SLC47A1—head—head and neck cancer	0.000438	0.00335	CbGeAlD
Imatinib—Urinary tract infection—Fluorouracil—head and neck cancer	0.000437	0.00196	CcSEcCtD
Imatinib—Conjunctivitis—Fluorouracil—head and neck cancer	0.000437	0.00196	CcSEcCtD
Imatinib—Leukopenia—Hydroxyurea—head and neck cancer	0.000437	0.00196	CcSEcCtD
Imatinib—KIT—head—head and neck cancer	0.000435	0.00334	CbGeAlD
Imatinib—Cardiac failure—Docetaxel—head and neck cancer	0.000432	0.00193	CcSEcCtD
Imatinib—Lethargy—Docetaxel—head and neck cancer	0.00043	0.00192	CcSEcCtD
Imatinib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000428	0.00192	CcSEcCtD
Imatinib—ABL1—thyroid gland—head and neck cancer	0.000427	0.00327	CbGeAlD
Imatinib—PDGFRB—head—head and neck cancer	0.000425	0.00326	CbGeAlD
Imatinib—Epistaxis—Fluorouracil—head and neck cancer	0.000424	0.0019	CcSEcCtD
Imatinib—Convulsion—Hydroxyurea—head and neck cancer	0.000423	0.00189	CcSEcCtD
Imatinib—Hyponatraemia—Docetaxel—head and neck cancer	0.000423	0.00189	CcSEcCtD
Imatinib—Sinusitis—Fluorouracil—head and neck cancer	0.000422	0.00189	CcSEcCtD
Imatinib—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000421	0.00189	CcSEcCtD
Imatinib—Pain in extremity—Docetaxel—head and neck cancer	0.000421	0.00189	CcSEcCtD
Imatinib—Agranulocytosis—Fluorouracil—head and neck cancer	0.00042	0.00188	CcSEcCtD
Imatinib—Anorexia—Vinblastine—head and neck cancer	0.000417	0.00187	CcSEcCtD
Imatinib—CA2—epithelium—head and neck cancer	0.000416	0.00319	CbGeAlD
Imatinib—Migraine—Docetaxel—head and neck cancer	0.000415	0.00186	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000413	0.00185	CcSEcCtD
Imatinib—Discomfort—Hydroxyurea—head and neck cancer	0.000411	0.00184	CcSEcCtD
Imatinib—Haemoglobin—Fluorouracil—head and neck cancer	0.000406	0.00182	CcSEcCtD
Imatinib—Rhinitis—Fluorouracil—head and neck cancer	0.000405	0.00181	CcSEcCtD
Imatinib—Haemorrhage—Fluorouracil—head and neck cancer	0.000404	0.00181	CcSEcCtD
Imatinib—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000402	0.0018	CcSEcCtD
Imatinib—Pharyngitis—Fluorouracil—head and neck cancer	0.000401	0.00179	CcSEcCtD
Imatinib—Oedema—Hydroxyurea—head and neck cancer	0.000399	0.00178	CcSEcCtD
Imatinib—CA1—head—head and neck cancer	0.000398	0.00305	CbGeAlD
Imatinib—Infection—Hydroxyurea—head and neck cancer	0.000396	0.00177	CcSEcCtD
Imatinib—Paraesthesia—Vinblastine—head and neck cancer	0.000392	0.00176	CcSEcCtD
Imatinib—Dehydration—Docetaxel—head and neck cancer	0.000392	0.00175	CcSEcCtD
Imatinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000391	0.00175	CcSEcCtD
Imatinib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00039	0.00175	CcSEcCtD
Imatinib—Skin disorder—Hydroxyurea—head and neck cancer	0.000387	0.00173	CcSEcCtD
Imatinib—Dry skin—Docetaxel—head and neck cancer	0.000386	0.00173	CcSEcCtD
Imatinib—Abdominal pain upper—Docetaxel—head and neck cancer	0.000385	0.00172	CcSEcCtD
Imatinib—NQO2—lymph node—head and neck cancer	0.000382	0.00293	CbGeAlD
Imatinib—PDGFRA—lymph node—head and neck cancer	0.000381	0.00292	CbGeAlD
Imatinib—Breast disorder—Docetaxel—head and neck cancer	0.000381	0.0017	CcSEcCtD
Imatinib—Anorexia—Hydroxyurea—head and neck cancer	0.00038	0.0017	CcSEcCtD
Imatinib—Decreased appetite—Vinblastine—head and neck cancer	0.00038	0.0017	CcSEcCtD
Imatinib—Cramp muscle—Docetaxel—head and neck cancer	0.000379	0.0017	CcSEcCtD
Imatinib—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000379	0.0017	CcSEcCtD
Imatinib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000379	0.0017	CcSEcCtD
Imatinib—ABL1—head—head and neck cancer	0.000379	0.0029	CbGeAlD
Imatinib—Nasopharyngitis—Docetaxel—head and neck cancer	0.000377	0.00169	CcSEcCtD
Imatinib—Pain—Vinblastine—head and neck cancer	0.000374	0.00167	CcSEcCtD
Imatinib—Constipation—Vinblastine—head and neck cancer	0.000374	0.00167	CcSEcCtD
Imatinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000372	0.00166	CcSEcCtD
Imatinib—CA2—trachea—head and neck cancer	0.000368	0.00282	CbGeAlD
Imatinib—SLC22A1—head—head and neck cancer	0.000365	0.0028	CbGeAlD
Imatinib—Dysphagia—Docetaxel—head and neck cancer	0.000364	0.00163	CcSEcCtD
Imatinib—Arrhythmia—Fluorouracil—head and neck cancer	0.000361	0.00162	CcSEcCtD
Imatinib—Feeling abnormal—Vinblastine—head and neck cancer	0.00036	0.00161	CcSEcCtD
Imatinib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000357	0.0016	CcSEcCtD
Imatinib—Alopecia—Fluorouracil—head and neck cancer	0.000357	0.0016	CcSEcCtD
Imatinib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000355	0.00159	CcSEcCtD
Imatinib—Angina pectoris—Docetaxel—head and neck cancer	0.000355	0.00159	CcSEcCtD
Imatinib—Somnolence—Hydroxyurea—head and neck cancer	0.000354	0.00159	CcSEcCtD
Imatinib—Erythema—Fluorouracil—head and neck cancer	0.000351	0.00157	CcSEcCtD
Imatinib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000351	0.00157	CcSEcCtD
Imatinib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000346	0.00155	CcSEcCtD
Imatinib—Pancytopenia—Docetaxel—head and neck cancer	0.000346	0.00155	CcSEcCtD
Imatinib—Abdominal pain—Vinblastine—head and neck cancer	0.000345	0.00155	CcSEcCtD
Imatinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000344	0.00154	CcSEcCtD
Imatinib—Fatigue—Hydroxyurea—head and neck cancer	0.000344	0.00154	CcSEcCtD
Imatinib—Pain—Hydroxyurea—head and neck cancer	0.000341	0.00153	CcSEcCtD
Imatinib—Constipation—Hydroxyurea—head and neck cancer	0.000341	0.00153	CcSEcCtD
Imatinib—Neutropenia—Docetaxel—head and neck cancer	0.00034	0.00152	CcSEcCtD
Imatinib—PTGS1—connective tissue—head and neck cancer	0.000338	0.00259	CbGeAlD
Imatinib—CSF1R—lymph node—head and neck cancer	0.000336	0.00257	CbGeAlD
Imatinib—Weight increased—Docetaxel—head and neck cancer	0.000331	0.00148	CcSEcCtD
Imatinib—Vision blurred—Fluorouracil—head and neck cancer	0.000331	0.00148	CcSEcCtD
Imatinib—Weight decreased—Docetaxel—head and neck cancer	0.000329	0.00147	CcSEcCtD
Imatinib—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000328	0.00147	CcSEcCtD
Imatinib—Pneumonia—Docetaxel—head and neck cancer	0.000327	0.00146	CcSEcCtD
Imatinib—Anaemia—Fluorouracil—head and neck cancer	0.000325	0.00145	CcSEcCtD
Imatinib—Infestation NOS—Docetaxel—head and neck cancer	0.000325	0.00145	CcSEcCtD
Imatinib—Infestation—Docetaxel—head and neck cancer	0.000325	0.00145	CcSEcCtD
Imatinib—Hypersensitivity—Vinblastine—head and neck cancer	0.000322	0.00144	CcSEcCtD
Imatinib—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000322	0.00144	CcSEcCtD
Imatinib—PTGS1—epithelium—head and neck cancer	0.000321	0.00246	CbGeAlD
Imatinib—CA2—lymphoid tissue—head and neck cancer	0.00032	0.00245	CbGeAlD
Imatinib—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00032	0.00143	CcSEcCtD
Imatinib—Renal failure—Docetaxel—head and neck cancer	0.000319	0.00143	CcSEcCtD
Imatinib—Myocardial infarction—Docetaxel—head and neck cancer	0.000318	0.00142	CcSEcCtD
Imatinib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000318	0.00142	CcSEcCtD
Imatinib—Stomatitis—Docetaxel—head and neck cancer	0.000316	0.00142	CcSEcCtD
Imatinib—Jaundice—Docetaxel—head and neck cancer	0.000316	0.00142	CcSEcCtD
Imatinib—Conjunctivitis—Docetaxel—head and neck cancer	0.000316	0.00141	CcSEcCtD
Imatinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000315	0.00141	CcSEcCtD
Imatinib—Leukopenia—Fluorouracil—head and neck cancer	0.000315	0.00141	CcSEcCtD
Imatinib—Asthenia—Vinblastine—head and neck cancer	0.000314	0.0014	CcSEcCtD
Imatinib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000307	0.00137	CcSEcCtD
Imatinib—SLC47A1—lymph node—head and neck cancer	0.000307	0.00235	CbGeAlD
Imatinib—Epistaxis—Docetaxel—head and neck cancer	0.000306	0.00137	CcSEcCtD
Imatinib—KIT—lymph node—head and neck cancer	0.000305	0.00234	CbGeAlD
Imatinib—Convulsion—Fluorouracil—head and neck cancer	0.000305	0.00136	CcSEcCtD
Imatinib—Agranulocytosis—Docetaxel—head and neck cancer	0.000303	0.00136	CcSEcCtD
Imatinib—Chest pain—Fluorouracil—head and neck cancer	0.000299	0.00134	CcSEcCtD
Imatinib—Myalgia—Fluorouracil—head and neck cancer	0.000299	0.00134	CcSEcCtD
Imatinib—Diarrhoea—Vinblastine—head and neck cancer	0.000299	0.00134	CcSEcCtD
Imatinib—PDGFRB—lymph node—head and neck cancer	0.000298	0.00228	CbGeAlD
Imatinib—Discomfort—Fluorouracil—head and neck cancer	0.000296	0.00132	CcSEcCtD
Imatinib—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000294	0.00131	CcSEcCtD
Imatinib—Haemoglobin—Docetaxel—head and neck cancer	0.000293	0.00131	CcSEcCtD
Imatinib—Rhinitis—Docetaxel—head and neck cancer	0.000292	0.00131	CcSEcCtD
Imatinib—Haemorrhage—Docetaxel—head and neck cancer	0.000291	0.0013	CcSEcCtD
Imatinib—Hepatitis—Docetaxel—head and neck cancer	0.000291	0.0013	CcSEcCtD
Imatinib—CA2—thyroid gland—head and neck cancer	0.000291	0.00223	CbGeAlD
Imatinib—Hypoaesthesia—Docetaxel—head and neck cancer	0.00029	0.0013	CcSEcCtD
Imatinib—Confusional state—Fluorouracil—head and neck cancer	0.000289	0.0013	CcSEcCtD
Imatinib—Pharyngitis—Docetaxel—head and neck cancer	0.000289	0.0013	CcSEcCtD
Imatinib—Dizziness—Vinblastine—head and neck cancer	0.000289	0.00129	CcSEcCtD
Imatinib—Urinary tract disorder—Docetaxel—head and neck cancer	0.000288	0.00129	CcSEcCtD
Imatinib—Oedema peripheral—Docetaxel—head and neck cancer	0.000287	0.00129	CcSEcCtD
Imatinib—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000287	0.00128	CcSEcCtD
Imatinib—Oedema—Fluorouracil—head and neck cancer	0.000287	0.00128	CcSEcCtD
Imatinib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000286	0.00128	CcSEcCtD
Imatinib—Asthenia—Hydroxyurea—head and neck cancer	0.000286	0.00128	CcSEcCtD
Imatinib—Urethral disorder—Docetaxel—head and neck cancer	0.000286	0.00128	CcSEcCtD
Imatinib—Infection—Fluorouracil—head and neck cancer	0.000285	0.00128	CcSEcCtD
Imatinib—PTGS1—trachea—head and neck cancer	0.000284	0.00218	CbGeAlD
Imatinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000281	0.00126	CcSEcCtD
Imatinib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000281	0.00126	CcSEcCtD
Imatinib—Tachycardia—Fluorouracil—head and neck cancer	0.00028	0.00125	CcSEcCtD
Imatinib—ORM1—lymph node—head and neck cancer	0.000279	0.00214	CbGeAlD
Imatinib—CA1—lymph node—head and neck cancer	0.000279	0.00214	CbGeAlD
Imatinib—Vomiting—Vinblastine—head and neck cancer	0.000278	0.00124	CcSEcCtD
Imatinib—Erythema multiforme—Docetaxel—head and neck cancer	0.000276	0.00123	CcSEcCtD
Imatinib—Headache—Vinblastine—head and neck cancer	0.000274	0.00123	CcSEcCtD
Imatinib—Anorexia—Fluorouracil—head and neck cancer	0.000273	0.00122	CcSEcCtD
Imatinib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000273	0.00122	CcSEcCtD
Imatinib—Eye disorder—Docetaxel—head and neck cancer	0.000272	0.00122	CcSEcCtD
Imatinib—Cardiac disorder—Docetaxel—head and neck cancer	0.00027	0.00121	CcSEcCtD
Imatinib—Flushing—Docetaxel—head and neck cancer	0.00027	0.00121	CcSEcCtD
Imatinib—ABCG2—thyroid gland—head and neck cancer	0.000269	0.00206	CbGeAlD
Imatinib—Hypotension—Fluorouracil—head and neck cancer	0.000268	0.0012	CcSEcCtD
Imatinib—ABL1—lymph node—head and neck cancer	0.000265	0.00203	CbGeAlD
Imatinib—Angiopathy—Docetaxel—head and neck cancer	0.000264	0.00118	CcSEcCtD
Imatinib—Dizziness—Hydroxyurea—head and neck cancer	0.000264	0.00118	CcSEcCtD
Imatinib—Immune system disorder—Docetaxel—head and neck cancer	0.000263	0.00118	CcSEcCtD
Imatinib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000263	0.00118	CcSEcCtD
Imatinib—Chills—Docetaxel—head and neck cancer	0.000261	0.00117	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000261	0.00117	CcSEcCtD
Imatinib—Arrhythmia—Docetaxel—head and neck cancer	0.00026	0.00117	CcSEcCtD
Imatinib—Nausea—Vinblastine—head and neck cancer	0.00026	0.00116	CcSEcCtD
Imatinib—Insomnia—Fluorouracil—head and neck cancer	0.000259	0.00116	CcSEcCtD
Imatinib—CYP1A2—thyroid gland—head and neck cancer	0.000259	0.00199	CbGeAlD
Imatinib—CA2—head—head and neck cancer	0.000258	0.00198	CbGeAlD
Imatinib—Paraesthesia—Fluorouracil—head and neck cancer	0.000258	0.00115	CcSEcCtD
Imatinib—Alopecia—Docetaxel—head and neck cancer	0.000258	0.00115	CcSEcCtD
Imatinib—Dyspnoea—Fluorouracil—head and neck cancer	0.000256	0.00115	CcSEcCtD
Imatinib—Mental disorder—Docetaxel—head and neck cancer	0.000255	0.00114	CcSEcCtD
Imatinib—Somnolence—Fluorouracil—head and neck cancer	0.000255	0.00114	CcSEcCtD
Imatinib—Malnutrition—Docetaxel—head and neck cancer	0.000254	0.00114	CcSEcCtD
Imatinib—Erythema—Docetaxel—head and neck cancer	0.000254	0.00114	CcSEcCtD
Imatinib—Vomiting—Hydroxyurea—head and neck cancer	0.000253	0.00113	CcSEcCtD
Imatinib—Dyspepsia—Fluorouracil—head and neck cancer	0.000252	0.00113	CcSEcCtD
Imatinib—Rash—Hydroxyurea—head and neck cancer	0.000251	0.00113	CcSEcCtD
Imatinib—Dermatitis—Hydroxyurea—head and neck cancer	0.000251	0.00112	CcSEcCtD
Imatinib—Headache—Hydroxyurea—head and neck cancer	0.00025	0.00112	CcSEcCtD
Imatinib—Decreased appetite—Fluorouracil—head and neck cancer	0.000249	0.00112	CcSEcCtD
Imatinib—Dysgeusia—Docetaxel—head and neck cancer	0.000248	0.00111	CcSEcCtD
Imatinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000248	0.00111	CcSEcCtD
Imatinib—Back pain—Docetaxel—head and neck cancer	0.000245	0.0011	CcSEcCtD
Imatinib—Pain—Fluorouracil—head and neck cancer	0.000245	0.0011	CcSEcCtD
Imatinib—ALB—lymph node—head and neck cancer	0.000245	0.00188	CbGeAlD
Imatinib—Muscle spasms—Docetaxel—head and neck cancer	0.000244	0.00109	CcSEcCtD
Imatinib—Nausea—Hydroxyurea—head and neck cancer	0.000237	0.00106	CcSEcCtD
Imatinib—Feeling abnormal—Fluorouracil—head and neck cancer	0.000236	0.00106	CcSEcCtD
Imatinib—Anaemia—Docetaxel—head and neck cancer	0.000234	0.00105	CcSEcCtD
Imatinib—Urticaria—Fluorouracil—head and neck cancer	0.000228	0.00102	CcSEcCtD
Imatinib—Syncope—Docetaxel—head and neck cancer	0.000227	0.00102	CcSEcCtD
Imatinib—Leukopenia—Docetaxel—head and neck cancer	0.000227	0.00102	CcSEcCtD
Imatinib—Body temperature increased—Fluorouracil—head and neck cancer	0.000227	0.00102	CcSEcCtD
Imatinib—PTGS1—thyroid gland—head and neck cancer	0.000225	0.00172	CbGeAlD
Imatinib—Palpitations—Docetaxel—head and neck cancer	0.000224	0.001	CcSEcCtD
Imatinib—Loss of consciousness—Docetaxel—head and neck cancer	0.000223	0.000998	CcSEcCtD
Imatinib—Cough—Docetaxel—head and neck cancer	0.000221	0.000991	CcSEcCtD
Imatinib—Convulsion—Docetaxel—head and neck cancer	0.00022	0.000984	CcSEcCtD
Imatinib—Hypertension—Docetaxel—head and neck cancer	0.000219	0.000981	CcSEcCtD
Imatinib—Myalgia—Docetaxel—head and neck cancer	0.000216	0.000967	CcSEcCtD
Imatinib—Arthralgia—Docetaxel—head and neck cancer	0.000216	0.000967	CcSEcCtD
Imatinib—Chest pain—Docetaxel—head and neck cancer	0.000216	0.000967	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000214	0.00096	CcSEcCtD
Imatinib—Hypersensitivity—Fluorouracil—head and neck cancer	0.000211	0.000946	CcSEcCtD
Imatinib—Dry mouth—Docetaxel—head and neck cancer	0.000211	0.000946	CcSEcCtD
Imatinib—Confusional state—Docetaxel—head and neck cancer	0.000209	0.000935	CcSEcCtD
Imatinib—Oedema—Docetaxel—head and neck cancer	0.000207	0.000927	CcSEcCtD
Imatinib—Anaphylactic shock—Docetaxel—head and neck cancer	0.000207	0.000927	CcSEcCtD
Imatinib—Infection—Docetaxel—head and neck cancer	0.000206	0.000921	CcSEcCtD
Imatinib—Shock—Docetaxel—head and neck cancer	0.000204	0.000912	CcSEcCtD
Imatinib—Nervous system disorder—Docetaxel—head and neck cancer	0.000203	0.000909	CcSEcCtD
Imatinib—Pruritus—Fluorouracil—head and neck cancer	0.000203	0.000909	CcSEcCtD
Imatinib—Thrombocytopenia—Docetaxel—head and neck cancer	0.000203	0.000908	CcSEcCtD
Imatinib—Tachycardia—Docetaxel—head and neck cancer	0.000202	0.000905	CcSEcCtD
Imatinib—Skin disorder—Docetaxel—head and neck cancer	0.000201	0.0009	CcSEcCtD
Imatinib—PTGS1—head—head and neck cancer	0.000199	0.00153	CbGeAlD
Imatinib—Anorexia—Docetaxel—head and neck cancer	0.000197	0.000884	CcSEcCtD
Imatinib—Diarrhoea—Fluorouracil—head and neck cancer	0.000196	0.000879	CcSEcCtD
Imatinib—Hypotension—Docetaxel—head and neck cancer	0.000193	0.000866	CcSEcCtD
Imatinib—ABCB1—epithelium—head and neck cancer	0.00019	0.00145	CbGeAlD
Imatinib—Dizziness—Fluorouracil—head and neck cancer	0.00019	0.000849	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000189	0.000845	CcSEcCtD
Imatinib—Insomnia—Docetaxel—head and neck cancer	0.000187	0.000838	CcSEcCtD
Imatinib—Paraesthesia—Docetaxel—head and neck cancer	0.000186	0.000832	CcSEcCtD
Imatinib—Dyspnoea—Docetaxel—head and neck cancer	0.000185	0.000826	CcSEcCtD
Imatinib—Somnolence—Docetaxel—head and neck cancer	0.000184	0.000824	CcSEcCtD
Imatinib—Vomiting—Fluorouracil—head and neck cancer	0.000182	0.000817	CcSEcCtD
Imatinib—Dyspepsia—Docetaxel—head and neck cancer	0.000182	0.000816	CcSEcCtD
Imatinib—Rash—Fluorouracil—head and neck cancer	0.000181	0.00081	CcSEcCtD
Imatinib—Dermatitis—Fluorouracil—head and neck cancer	0.000181	0.000809	CcSEcCtD
Imatinib—CA2—lymph node—head and neck cancer	0.000181	0.00138	CbGeAlD
Imatinib—Decreased appetite—Docetaxel—head and neck cancer	0.00018	0.000806	CcSEcCtD
Imatinib—Headache—Fluorouracil—head and neck cancer	0.00018	0.000805	CcSEcCtD
Imatinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000179	0.0008	CcSEcCtD
Imatinib—Fatigue—Docetaxel—head and neck cancer	0.000178	0.000799	CcSEcCtD
Imatinib—Constipation—Docetaxel—head and neck cancer	0.000177	0.000793	CcSEcCtD
Imatinib—Pain—Docetaxel—head and neck cancer	0.000177	0.000793	CcSEcCtD
Imatinib—Feeling abnormal—Docetaxel—head and neck cancer	0.000171	0.000764	CcSEcCtD
Imatinib—Nausea—Fluorouracil—head and neck cancer	0.00017	0.000763	CcSEcCtD
Imatinib—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000169	0.000758	CcSEcCtD
Imatinib—ABCB1—trachea—head and neck cancer	0.000168	0.00129	CbGeAlD
Imatinib—ABCG2—lymph node—head and neck cancer	0.000167	0.00128	CbGeAlD
Imatinib—CYP2D6—head—head and neck cancer	0.000164	0.00126	CbGeAlD
Imatinib—Body temperature increased—Docetaxel—head and neck cancer	0.000164	0.000733	CcSEcCtD
Imatinib—Abdominal pain—Docetaxel—head and neck cancer	0.000164	0.000733	CcSEcCtD
Imatinib—Hypersensitivity—Docetaxel—head and neck cancer	0.000153	0.000683	CcSEcCtD
Imatinib—Asthenia—Docetaxel—head and neck cancer	0.000149	0.000665	CcSEcCtD
Imatinib—Pruritus—Docetaxel—head and neck cancer	0.000146	0.000656	CcSEcCtD
Imatinib—ABCB1—lymphoid tissue—head and neck cancer	0.000146	0.00112	CbGeAlD
Imatinib—Diarrhoea—Docetaxel—head and neck cancer	0.000142	0.000634	CcSEcCtD
Imatinib—PTGS1—lymph node—head and neck cancer	0.00014	0.00107	CbGeAlD
Imatinib—Dizziness—Docetaxel—head and neck cancer	0.000137	0.000613	CcSEcCtD
Imatinib—ABCB1—thyroid gland—head and neck cancer	0.000133	0.00102	CbGeAlD
Imatinib—Vomiting—Docetaxel—head and neck cancer	0.000132	0.000589	CcSEcCtD
Imatinib—Rash—Docetaxel—head and neck cancer	0.000131	0.000585	CcSEcCtD
Imatinib—Dermatitis—Docetaxel—head and neck cancer	0.00013	0.000584	CcSEcCtD
Imatinib—Headache—Docetaxel—head and neck cancer	0.00013	0.000581	CcSEcCtD
Imatinib—Nausea—Docetaxel—head and neck cancer	0.000123	0.000551	CcSEcCtD
Imatinib—ABCB1—head—head and neck cancer	0.000118	0.000903	CbGeAlD
Imatinib—ABCB1—lymph node—head and neck cancer	8.25e-05	0.000632	CbGeAlD
Imatinib—PDGFRB—Innate Immune System—AKT1—head and neck cancer	1.39e-05	8.05e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PTEN—head and neck cancer	1.37e-05	7.93e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IL2—head and neck cancer	1.37e-05	7.91e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—PIK3CA—head and neck cancer	1.37e-05	7.91e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—BCL2—head and neck cancer	1.36e-05	7.88e-05	CbGpPWpGaD
Imatinib—KIT—Disease—STAT3—head and neck cancer	1.36e-05	7.88e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—AKT1—head and neck cancer	1.36e-05	7.85e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.34e-05	7.77e-05	CbGpPWpGaD
Imatinib—CA1—Metabolism—PIK3CA—head and neck cancer	1.34e-05	7.77e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—MAPK1—head and neck cancer	1.34e-05	7.76e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—EGFR—head and neck cancer	1.34e-05	7.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—AKT1—head and neck cancer	1.34e-05	7.73e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—MAPK3—head and neck cancer	1.33e-05	7.72e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—DPYD—head and neck cancer	1.32e-05	7.62e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—VEGFA—head and neck cancer	1.31e-05	7.61e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—PIK3CA—head and neck cancer	1.31e-05	7.6e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—STAT3—head and neck cancer	1.3e-05	7.53e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MAPK3—head and neck cancer	1.3e-05	7.53e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PTEN—head and neck cancer	1.3e-05	7.51e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—STAT3—head and neck cancer	1.29e-05	7.46e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.29e-05	7.44e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—MAPK1—head and neck cancer	1.27e-05	7.34e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—EGFR—head and neck cancer	1.27e-05	7.34e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—HRAS—head and neck cancer	1.26e-05	7.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—STAT3—head and neck cancer	1.26e-05	7.28e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—YAP1—head and neck cancer	1.25e-05	7.23e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—TYMS—head and neck cancer	1.25e-05	7.21e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MAPK3—head and neck cancer	1.24e-05	7.19e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—AKT1—head and neck cancer	1.24e-05	7.18e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MAPK1—head and neck cancer	1.24e-05	7.16e-05	CbGpPWpGaD
Imatinib—KIT—Disease—EGFR—head and neck cancer	1.24e-05	7.16e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GSTM1—head and neck cancer	1.23e-05	7.13e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MAPK3—head and neck cancer	1.23e-05	7.13e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—STAT3—head and neck cancer	1.23e-05	7.09e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—HRAS—head and neck cancer	1.21e-05	7.03e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.21e-05	6.98e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MAPK3—head and neck cancer	1.2e-05	6.95e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2—head and neck cancer	1.2e-05	6.94e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTGS2—head and neck cancer	1.19e-05	6.91e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MAPK1—head and neck cancer	1.18e-05	6.85e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—EGFR—head and neck cancer	1.18e-05	6.84e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—PIK3CA—head and neck cancer	1.18e-05	6.83e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GPX1—head and neck cancer	1.18e-05	6.83e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MAPK1—head and neck cancer	1.17e-05	6.78e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—EGFR—head and neck cancer	1.17e-05	6.78e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.17e-05	6.78e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—MAPK3—head and neck cancer	1.17e-05	6.78e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CYP1A1—head and neck cancer	1.17e-05	6.76e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—PIK3CA—head and neck cancer	1.16e-05	6.73e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—VEGFA—head and neck cancer	1.16e-05	6.72e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—STAT3—head and neck cancer	1.16e-05	6.72e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—NAT2—head and neck cancer	1.16e-05	6.71e-05	CbGpPWpGaD
Imatinib—CA2—Metabolism—AKT1—head and neck cancer	1.14e-05	6.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—MAPK1—head and neck cancer	1.14e-05	6.62e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—EGFR—head and neck cancer	1.14e-05	6.61e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2—head and neck cancer	1.13e-05	6.56e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PTEN—head and neck cancer	1.13e-05	6.53e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—NOTCH1—head and neck cancer	1.13e-05	6.52e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—AKT1—head and neck cancer	1.12e-05	6.46e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—MAPK1—head and neck cancer	1.11e-05	6.45e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—EGFR—head and neck cancer	1.11e-05	6.45e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MAPK3—head and neck cancer	1.11e-05	6.42e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CCND1—head and neck cancer	1.1e-05	6.39e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—PIK3CA—head and neck cancer	1.1e-05	6.37e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.1e-05	6.36e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—MAPK3—head and neck cancer	1.1e-05	6.36e-05	CbGpPWpGaD
Imatinib—CA1—Metabolism—AKT1—head and neck cancer	1.1e-05	6.34e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—HRAS—head and neck cancer	1.08e-05	6.23e-05	CbGpPWpGaD
Imatinib—KIT—Disease—PIK3CA—head and neck cancer	1.07e-05	6.22e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—TYMS—head and neck cancer	1.07e-05	6.21e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—head and neck cancer	1.07e-05	6.21e-05	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—head and neck cancer	1.07e-05	6.2e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PTEN—head and neck cancer	1.07e-05	6.17e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GSTM1—head and neck cancer	1.06e-05	6.14e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MAPK1—head and neck cancer	1.06e-05	6.11e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—EGFR—head and neck cancer	1.06e-05	6.11e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.05e-05	6.08e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—MAPK1—head and neck cancer	1.05e-05	6.05e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CCND1—head and neck cancer	1.05e-05	6.05e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PTEN—head and neck cancer	1.04e-05	6.03e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—PIK3CA—head and neck cancer	1.03e-05	5.94e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—HRAS—head and neck cancer	1.02e-05	5.9e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—DPYD—head and neck cancer	1.02e-05	5.88e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—PIK3CA—head and neck cancer	1.02e-05	5.88e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GPX1—head and neck cancer	1.02e-05	5.88e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—STAT3—head and neck cancer	1.01e-05	5.84e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PTEN—head and neck cancer	1.01e-05	5.84e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP1A1—head and neck cancer	1.01e-05	5.82e-05	CbGpPWpGaD
Imatinib—KIT—Disease—HRAS—head and neck cancer	9.93e-06	5.75e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—head and neck cancer	9.93e-06	5.75e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—PIK3CA—head and neck cancer	9.92e-06	5.74e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTGS2—head and neck cancer	9.69e-06	5.61e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—PIK3CA—head and neck cancer	9.66e-06	5.59e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—head and neck cancer	9.66e-06	5.59e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—YAP1—head and neck cancer	9.65e-06	5.58e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK3—head and neck cancer	9.64e-06	5.58e-05	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—head and neck cancer	9.64e-06	5.58e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TYMS—head and neck cancer	9.63e-06	5.58e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—VEGFA—head and neck cancer	9.63e-06	5.57e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTGS2—head and neck cancer	9.6e-06	5.56e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTGS2—head and neck cancer	9.59e-06	5.55e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	9.58e-06	5.55e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—STAT3—head and neck cancer	9.53e-06	5.52e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GSTM1—head and neck cancer	9.52e-06	5.51e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—head and neck cancer	9.5e-06	5.5e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—HRAS—head and neck cancer	9.49e-06	5.5e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CCND1—head and neck cancer	9.42e-06	5.45e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—HRAS—head and neck cancer	9.4e-06	5.44e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TYMS—head and neck cancer	9.4e-06	5.44e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	9.39e-06	5.44e-05	CbGpPWpGaD
Imatinib—LCK—Disease—STAT3—head and neck cancer	9.32e-06	5.39e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTGS2—head and neck cancer	9.31e-06	5.39e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GSTM1—head and neck cancer	9.29e-06	5.38e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—HRAS—head and neck cancer	9.18e-06	5.31e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—MAPK1—head and neck cancer	9.17e-06	5.31e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—EGFR—head and neck cancer	9.17e-06	5.31e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—PIK3CA—head and neck cancer	9.16e-06	5.3e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GPX1—head and neck cancer	9.12e-06	5.28e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—VEGFA—head and neck cancer	9.11e-06	5.27e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK3—head and neck cancer	9.11e-06	5.27e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PTEN—head and neck cancer	9.09e-06	5.26e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—PIK3CA—head and neck cancer	9.07e-06	5.25e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP1A1—head and neck cancer	9.03e-06	5.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—STAT3—head and neck cancer	9.02e-06	5.22e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—head and neck cancer	8.99e-06	5.21e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—HRAS—head and neck cancer	8.94e-06	5.18e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTGS2—head and neck cancer	8.94e-06	5.17e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK3—head and neck cancer	8.9e-06	5.15e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GPX1—head and neck cancer	8.9e-06	5.15e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TYMS—head and neck cancer	8.86e-06	5.13e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP1A1—head and neck cancer	8.81e-06	5.1e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TYMS—head and neck cancer	8.78e-06	5.08e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—head and neck cancer	8.78e-06	5.08e-05	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—head and neck cancer	8.77e-06	5.08e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GSTM1—head and neck cancer	8.76e-06	5.07e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GSTM1—head and neck cancer	8.68e-06	5.03e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAPK1—head and neck cancer	8.66e-06	5.02e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—EGFR—head and neck cancer	8.66e-06	5.01e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK3—head and neck cancer	8.62e-06	4.99e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—HRAS—head and neck cancer	8.47e-06	4.9e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MAPK1—head and neck cancer	8.47e-06	4.9e-05	CbGpPWpGaD
Imatinib—LCK—Disease—EGFR—head and neck cancer	8.47e-06	4.9e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PTEN—head and neck cancer	8.45e-06	4.89e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—HRAS—head and neck cancer	8.39e-06	4.86e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX1—head and neck cancer	8.39e-06	4.85e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—head and neck cancer	8.38e-06	4.85e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PTEN—head and neck cancer	8.38e-06	4.85e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PTEN—head and neck cancer	8.36e-06	4.84e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX1—head and neck cancer	8.31e-06	4.81e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—head and neck cancer	8.3e-06	4.81e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP1A1—head and neck cancer	8.3e-06	4.81e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	8.26e-06	4.78e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP1A1—head and neck cancer	8.23e-06	4.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—VEGFA—head and neck cancer	8.21e-06	4.75e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAPK1—head and neck cancer	8.2e-06	4.75e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—EGFR—head and neck cancer	8.2e-06	4.75e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.19e-06	4.74e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—STAT3—head and neck cancer	8.13e-06	4.71e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PTEN—head and neck cancer	8.12e-06	4.7e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—head and neck cancer	8.1e-06	4.69e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—PIK3CA—head and neck cancer	7.96e-06	4.61e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—head and neck cancer	7.9e-06	4.57e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PTEN—head and neck cancer	7.8e-06	4.51e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK3—head and neck cancer	7.77e-06	4.5e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—head and neck cancer	7.75e-06	4.49e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CCND1—head and neck cancer	7.56e-06	4.37e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—PIK3CA—head and neck cancer	7.52e-06	4.35e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TYMS—head and neck cancer	7.51e-06	4.34e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—head and neck cancer	7.48e-06	4.33e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GSTM1—head and neck cancer	7.42e-06	4.29e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.42e-06	4.29e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—head and neck cancer	7.41e-06	4.29e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAPK1—head and neck cancer	7.39e-06	4.28e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—EGFR—head and neck cancer	7.39e-06	4.28e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—HRAS—head and neck cancer	7.36e-06	4.26e-05	CbGpPWpGaD
Imatinib—LCK—Disease—PIK3CA—head and neck cancer	7.35e-06	4.25e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PTEN—head and neck cancer	7.29e-06	4.22e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—head and neck cancer	7.27e-06	4.21e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—PIK3CA—head and neck cancer	7.12e-06	4.12e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX1—head and neck cancer	7.1e-06	4.11e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP1A1—head and neck cancer	7.03e-06	4.07e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—HRAS—head and neck cancer	6.96e-06	4.03e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTGS2—head and neck cancer	6.94e-06	4.02e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—head and neck cancer	6.89e-06	3.99e-05	CbGpPWpGaD
Imatinib—LCK—Disease—HRAS—head and neck cancer	6.8e-06	3.94e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.76e-06	3.91e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—VEGFA—head and neck cancer	6.59e-06	3.81e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—HRAS—head and neck cancer	6.58e-06	3.81e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—STAT3—head and neck cancer	6.52e-06	3.78e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—head and neck cancer	6.5e-06	3.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—PIK3CA—head and neck cancer	6.41e-06	3.71e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK3—head and neck cancer	6.23e-06	3.61e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—head and neck cancer	6.2e-06	3.59e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—head and neck cancer	6.14e-06	3.56e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PTEN—head and neck cancer	6.05e-06	3.5e-05	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—head and neck cancer	6e-06	3.47e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTGS2—head and neck cancer	5.98e-06	3.46e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—PIK3CA—head and neck cancer	5.96e-06	3.45e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—HRAS—head and neck cancer	5.93e-06	3.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAPK1—head and neck cancer	5.93e-06	3.43e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—EGFR—head and neck cancer	5.93e-06	3.43e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—PIK3CA—head and neck cancer	5.91e-06	3.42e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—PIK3CA—head and neck cancer	5.9e-06	3.42e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—head and neck cancer	5.81e-06	3.37e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TYMS—head and neck cancer	5.79e-06	3.35e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.78e-06	3.34e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—PIK3CA—head and neck cancer	5.73e-06	3.32e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GSTM1—head and neck cancer	5.73e-06	3.31e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—PIK3CA—head and neck cancer	5.5e-06	3.18e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX1—head and neck cancer	5.48e-06	3.17e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	5.43e-06	3.14e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTGS2—head and neck cancer	5.37e-06	3.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTGS2—head and neck cancer	5.24e-06	3.03e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—head and neck cancer	5.24e-06	3.03e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PTEN—head and neck cancer	5.21e-06	3.02e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—PIK3CA—head and neck cancer	5.15e-06	2.98e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—head and neck cancer	4.98e-06	2.88e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTGS2—head and neck cancer	4.94e-06	2.86e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTGS2—head and neck cancer	4.89e-06	2.83e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—head and neck cancer	4.87e-06	2.82e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—head and neck cancer	4.83e-06	2.79e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—head and neck cancer	4.82e-06	2.79e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—HRAS—head and neck cancer	4.76e-06	2.76e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PTEN—head and neck cancer	4.68e-06	2.71e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—head and neck cancer	4.68e-06	2.71e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PTEN—head and neck cancer	4.57e-06	2.64e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—head and neck cancer	4.49e-06	2.6e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PTEN—head and neck cancer	4.31e-06	2.49e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PIK3CA—head and neck cancer	4.27e-06	2.47e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PTEN—head and neck cancer	4.27e-06	2.47e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—head and neck cancer	4.2e-06	2.43e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTGS2—head and neck cancer	4.18e-06	2.42e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PIK3CA—head and neck cancer	3.68e-06	2.13e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PTEN—head and neck cancer	3.65e-06	2.11e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—head and neck cancer	3.49e-06	2.02e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PIK3CA—head and neck cancer	3.3e-06	1.91e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTGS2—head and neck cancer	3.23e-06	1.87e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PIK3CA—head and neck cancer	3.22e-06	1.87e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PIK3CA—head and neck cancer	3.04e-06	1.76e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PIK3CA—head and neck cancer	3.01e-06	1.74e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—head and neck cancer	3.01e-06	1.74e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PTEN—head and neck cancer	2.81e-06	1.63e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—head and neck cancer	2.7e-06	1.56e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—head and neck cancer	2.63e-06	1.52e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PIK3CA—head and neck cancer	2.57e-06	1.49e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—head and neck cancer	2.48e-06	1.44e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—head and neck cancer	2.46e-06	1.42e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—head and neck cancer	2.1e-06	1.22e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.99e-06	1.15e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—head and neck cancer	1.62e-06	9.39e-06	CbGpPWpGaD
